Details of the agreement
According to Metis TechBio, the company will be eligible for an upfront payment in the low double-digit millions of dollars, plus milestone payments of up to about $1.1 billion.
Key terms:
- Total value: up to about $1.1 billion.
- Upfront payment: in the low double-digit millions of dollars.
- Development, regulatory and commercial milestone payments.
- Tiered royalties at a single-digit percentage of annual net sales.
- Field: LNP-based tissue-specific drug delivery technology.
AI in lipid nanoparticle discovery
Metis will use its proprietary AI platform to discover and optimise ionizable lipids, a key component of lipid nanoparticles, to improve the targeting and biodistribution of LNP-based therapies.
The two companies aim to discover and optimise novel LNP architectures that could improve tissue specificity and therapeutic performance, with potential applications across multiple disease areas.
















